Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 14.18
KMDA's Cash to Debt is ranked lower than
55% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. KMDA: 14.18 )
Ranked among companies with meaningful Cash to Debt only.
KMDA' s Cash to Debt Range Over the Past 10 Years
Min: 1.32  Med: 6.71 Max: N/A
Current: 14.18
Equity to Asset 0.73
KMDA's Equity to Asset is ranked higher than
56% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. KMDA: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
KMDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.65 Max: 0.73
Current: 0.73
0.28
0.73
F-Score: 5
Z-Score: 4.69
M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -3.54
KMDA's Operating margin (%) is ranked higher than
70% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. KMDA: -3.54 )
Ranked among companies with meaningful Operating margin (%) only.
KMDA' s Operating margin (%) Range Over the Past 10 Years
Min: -121.42  Med: -16.34 Max: 5.83
Current: -3.54
-121.42
5.83
Net-margin (%) -4.99
KMDA's Net-margin (%) is ranked higher than
69% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. KMDA: -4.99 )
Ranked among companies with meaningful Net-margin (%) only.
KMDA' s Net-margin (%) Range Over the Past 10 Years
Min: -170.4  Med: -18.59 Max: 0.63
Current: -4.99
-170.4
0.63
ROE (%) -5.58
KMDA's ROE (%) is ranked higher than
71% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. KMDA: -5.58 )
Ranked among companies with meaningful ROE (%) only.
KMDA' s ROE (%) Range Over the Past 10 Years
Min: -196.88  Med: -15.31 Max: 1.02
Current: -5.58
-196.88
1.02
ROA (%) -3.86
KMDA's ROA (%) is ranked higher than
74% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. KMDA: -3.86 )
Ranked among companies with meaningful ROA (%) only.
KMDA' s ROA (%) Range Over the Past 10 Years
Min: -59.18  Med: -10.21 Max: 0.39
Current: -3.86
-59.18
0.39
ROC (Joel Greenblatt) (%) -4.76
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. KMDA: -4.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KMDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -179.58  Med: -24.2 Max: 15.92
Current: -4.76
-179.58
15.92
Revenue Growth (3Y)(%) -8.80
KMDA's Revenue Growth (3Y)(%) is ranked lower than
66% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. KMDA: -8.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KMDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.8  Med: 9.05 Max: 50.5
Current: -8.8
-8.8
50.5
» KMDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

KMDA Guru Trades in Q4 2015

Jim Simons 166,300 sh (+6.26%)
John Paulson 739,356 sh (unchged)
» More
Q1 2016

KMDA Guru Trades in Q1 2016

Jim Simons 170,300 sh (+2.41%)
John Paulson 736,117 sh (-0.44%)
» More
Q2 2016

KMDA Guru Trades in Q2 2016

Jim Simons 172,800 sh (+1.47%)
John Paulson 736,117 sh (unchged)
» More
Q3 2016

KMDA Guru Trades in Q3 2016

Jim Simons 188,500 sh (+9.09%)
John Paulson 730,800 sh (-0.72%)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CYAD, NAS:DVAX, NAS:EGLT, NAS:VTVT, OTCPK:DGJI, OTCPK:SPHRY, NAS:ALBO, NAS:VTL, NAS:MDGL, NAS:CBMG, NAS:CDTX, OTCPK:NICXF, NAS:PRTO, NAS:AGTC, NAS:IMDZ, NAS:VCYT, NAS:CDXS, NAS:ARGS, AMEX:PIP, NAS:IMGN » details
Traded in other countries:K3M.Germany, KMDA.Israel,
Kamada Ltd is an orphan drug, plasma-derived protein Therapeutics Company and develops & produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.

Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.

Ratios

vs
industry
vs
history
P/B 3.09
KMDA's P/B is ranked higher than
57% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. KMDA: 3.09 )
Ranked among companies with meaningful P/B only.
KMDA' s P/B Range Over the Past 10 Years
Min: 1.48  Med: 2.5 Max: 12.04
Current: 3.09
1.48
12.04
P/S 2.72
KMDA's P/S is ranked higher than
81% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. KMDA: 2.72 )
Ranked among companies with meaningful P/S only.
KMDA' s P/S Range Over the Past 10 Years
Min: 1.56  Med: 2.47 Max: 7.32
Current: 2.72
1.56
7.32
EV-to-EBIT -84.25
KMDA's EV-to-EBIT is ranked lower than
99.99% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. KMDA: -84.25 )
Ranked among companies with meaningful EV-to-EBIT only.
KMDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -84.25  Med: -9.4 Max: 201.8
Current: -84.25
-84.25
201.8
EV-to-EBITDA 158.49
KMDA's EV-to-EBITDA is ranked lower than
94% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. KMDA: 158.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
KMDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -67  Med: -11.65 Max: 158.49
Current: 158.49
-67
158.49
Current Ratio 3.90
KMDA's Current Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. KMDA: 3.90 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.29 Max: 4.42
Current: 3.9
2.21
4.42
Quick Ratio 2.41
KMDA's Quick Ratio is ranked lower than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. KMDA: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.32 Max: 3.59
Current: 2.41
1.45
3.59
Days Inventory 190.41
KMDA's Days Inventory is ranked lower than
68% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. KMDA: 190.41 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 97.6  Med: 142.69 Max: 190.41
Current: 190.41
97.6
190.41
Days Sales Outstanding 85.69
KMDA's Days Sales Outstanding is ranked lower than
67% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. KMDA: 85.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.76  Med: 95.09 Max: 135.5
Current: 85.69
45.76
135.5
Days Payable 92.06
KMDA's Days Payable is ranked higher than
66% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. KMDA: 92.06 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 115.23 Max: 174.99
Current: 92.06
89.24
174.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
KMDA's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. KMDA: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KMDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33.2  Med: -11.05 Max: -4.6
Current: -8.3
-33.2
-4.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 195.00
KMDA's Price/Net Cash is ranked lower than
98% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. KMDA: 195.00 )
Ranked among companies with meaningful Price/Net Cash only.
KMDA' s Price/Net Cash Range Over the Past 10 Years
Min: 10.31  Med: 18.07 Max: 355
Current: 195
10.31
355
Price/Net Current Asset Value 4.43
KMDA's Price/Net Current Asset Value is ranked higher than
61% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. KMDA: 4.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KMDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.32  Med: 3.84 Max: 40.62
Current: 4.43
2.32
40.62
Price/Tangible Book 3.08
KMDA's Price/Tangible Book is ranked higher than
65% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. KMDA: 3.08 )
Ranked among companies with meaningful Price/Tangible Book only.
KMDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.69  Med: 2.68 Max: 10.64
Current: 3.08
1.69
10.64
Price/Median PS Value 1.11
KMDA's Price/Median PS Value is ranked lower than
57% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. KMDA: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
KMDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 0.97 Max: 2.66
Current: 1.11
0.74
2.66
Earnings Yield (Greenblatt) (%) -1.19
KMDA's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. KMDA: -1.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KMDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.22  Med: 0.9 Max: 2
Current: -1.19
-1.22
2

More Statistics

Revenue (TTM) (Mil) $78.90
EPS (TTM) $ -0.10
Beta1.04
Short Percentage of Float0.05%
52-Week Range $3.26 - 6.29
Shares Outstanding (Mil)36.42

Analyst Estimate

Dec16 Dec18 Dec19
Revenue (Mil $) 326 421 600
EPS ($) -1.00 1.77 3.34
EPS w/o NRI ($) -1.00 1.77 3.34
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
ETFs with exposure to Kamada Ltd. : December 2, 2016 Dec 02 2016
Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Kamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1... Nov 15 2016
Can Agilent Technologies (A) Pull a Surprise in Q4 Earnings? Nov 14 2016
Kamada reports 3Q loss Nov 10 2016
Kamada reports 3Q loss Nov 10 2016
Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016 Nov 10 2016
Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016 Nov 10 2016
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies... Nov 07 2016
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies... Nov 07 2016
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies... Nov 07 2016
Kamada to Host Third Quarter Financial Results Conference Call on November 10, 2016 at 8:30 am... Nov 03 2016
Kamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of... Nov 02 2016
Kamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of... Nov 02 2016
Kamada (KMDA) Extends Partnership with Shire for Glassia Oct 10 2016
Kamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Shire with Minimum... Oct 06 2016
LifeSci Capital Initiates Coverage of Kamada Sep 12 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment Sep 01 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment Sep 01 2016
Kamada's Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint Aug 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)